pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: Immunotherapy

Sep 29, 2023

Therapeutic Solutions International Announces Paradigm Shifting Immunotherapy Product: Tolerogenic Neutrophils

Sep 27, 2023

HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting

Sep 27, 2023

Tallac Therapeutics Announces Two Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Sep 15, 2023

Therapeutic Solutions International Subsidiary Discloses Potential Solution to Immunotherapy Resistance in Cancer by “Healing Tumor” Before Killing It

Sep 13, 2023

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Aug 8, 2023

Imvax Announces Publication in Journal for ImmunoTherapy of Cancer Showing IGV-001 Can Induce Clinically Relevant Anti-Cancer Immune Responses in Glioblastoma via Immunogenic Cell Death

Aug 7, 2023

XNK Therapeutics to present two abstracts at the Society for Immunotherapy of Cancer's meeting in San Diego in November USA - English USA - English

Jul 18, 2023

Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene™

Jun 29, 2023

Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies

Jun 12, 2023

CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment

May 25, 2023

Cartography Biosciences Appoints Industry Veteran as Chief Administrative and Legal Officer

May 23, 2023

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

May 22, 2023

Therapeutic Solutions International Spin-Off Res Nova Bio Leverages FDA Cleared Tumor Blood Vessel Targeting Technology to Intravenously Deliver Cancer Killing Viruses

May 22, 2023

Outpace Bio Expands Seattle Presence with Cell Therapy Research Hub and Collaborations with Leading Experts in Protein Design and Cancer Immunotherapy

May 18, 2023

Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline

May 18, 2023

SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy

May 15, 2023

Therapeutic Solutions International Spin-Off Res Nova Bio Partners with Cure Stat Rx to Manufacture First in Class Breast Cancer Immunotherapy Product FloraStilbene™

Apr 19, 2023

Ankyra Therapeutics Presents Preliminary Canine Clinical Data with cANK-101 Supporting Therapeutic Potential of Anchored Immunotherapy

Apr 18, 2023

Turn Biotechnologies to Present Data at AACR Showing Epigenetic Reprogramming with ERA™ Technology Improves T Cell Immunotherapy

Mar 29, 2023

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients USA - English APAC - English

Mar 29, 2023

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients

Mar 29, 2023

Synthetic mRNA Market for Cancer Treatment size to grow at a CAGR of 13.4% by 2029: Growth opportunities led by BioNTech SE, Moderna Inc., CureVac AG, eTheRNA immunotherapies NV - Brandessence Market Research

Mar 28, 2023

Morphogenesis Inc. Acquires TυHURA Biopharma’s First-in-Class Antibody Drug Conjugates (ADCs) Technology Designed to Overcome Acquired Resistance to Cancer Immunotherapy

Mar 22, 2023

EvolveImmune Therapeutics Presents New Preclinical Data Demonstrating Improved Anti-Tumor Potential of Novel Costimulatory T Cell Engager Platform at Festival of Biologics Immunotherapy World Congress

Mar 16, 2023

AIVITA Biomedical Chief Medical Officer Dr. Robert Dillman to Deliver Keynote at World Immunotherapy Congress

Mar 6, 2023

Virion Therapeutics Presents Promising Preclinical Cancer Data When Using a Novel Genetically Encoded Checkpoint Modifier-Based Immunotherapy

Feb 21, 2023

Myeloid Therapeutics and New South Wales (NSW) Government in Australia Announce Collaboration to Design, Build, and Launch State-of-the-Art GMP Manufacturing Facility Dedicated to RNA Immunotherapies

Feb 6, 2023

Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program USA - English España - español USA - English Deutschland - Deutsch France - Français

Feb 6, 2023

Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program USA - English USA - español USA - English USA - Deutsch USA - Français

Jan 31, 2023

Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board

Jan 30, 2023

Therapeutic Solutions International Spin Off Res Nova Bio Announces Recruitment of President and Chief Executive Officer

Jan 17, 2023

Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid Tumors

Jan 9, 2023

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

Jan 4, 2023

Elpiscience to Present Its Novel Immunotherapies at Biotech Showcase™ during J.P. Morgan Week 2023

Dec 6, 2022

Candel Therapeutics RandD Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer

Nov 30, 2022

Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors USA - English USA - English

Nov 30, 2022

Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors

Nov 29, 2022

AIVITA Biomedical Chief Medical Officer Dr. Robert O. Dillman to Deliver Keynote and Chair Cancer Immunotherapy Track at World Vaccine and Immunotherapy Congress

Nov 29, 2022

Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy

Nov 22, 2022

Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer

Nov 17, 2022

Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma USA - English USA - English

Nov 17, 2022

Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma

Nov 16, 2022

Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022

Nov 15, 2022

Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer

Nov 14, 2022

OncoNano Medicine Announces New Preclinical Data for ON-BOARD™ Platform for Delivery of Bispecific T Cell Engagers and a Therapeutic Cytokine at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 11, 2022

Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting

Nov 11, 2022

Nutcracker Therapeutics Reports Strong Anti-Tumor Responses of Lead mRNA Immunotherapy in Preclinical Data Presented at SITC Annual Meeting 2022

Nov 10, 2022

HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting

Nov 10, 2022

Enterome's OncoMimics™ peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma

Nov 10, 2022

Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting

Nov 10, 2022

Myeloid Therapeutics Presents Update On Myeloid Cell Programming Technologies, Including Non-Human Primate Proof-Of-Concept Data Delivering in vivo mRNA TROP-2 Targeting CAR (MT-302) at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Nov 10, 2022

Imvax Presents Preclinical Data at SITC 2022 Supporting Mechanism of Action and Anti-tumor Activity of its Immunotherapy Platform Across Multiple Tumor Types

Nov 10, 2022

Ankyra Therapeutics Presents Positive Preclinical Data Supporting Advancement of ANK-101 into Clinical Studies for Treatment of Solid Tumors

Nov 10, 2022

Asher Bio Presents New Preclinical Data at SITC 2022 Further Supporting Advancement of AB248 and AB821 as Highly Differentiated Cis-targeted Cancer Immunotherapies

Nov 10, 2022

OncoNano Medicine Announces Pre-Clinical Data for Dual-Activating STING agonist at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 10, 2022

Aulos Bioscience Presents Initial Data From First-in-Human Phase 1/2 Clinical Trial of Computationally Designed Antibody AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 10, 2022

EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 10, 2022

Umoja Biopharma Presents New Preclinical Data on its Integrated In Vivo CAR T and Engineered Induced Pluripotent Stem Cell Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Nov 9, 2022

Kinimmune wins highly competitive NCI funding to advance solid tumor immunotherapy for patients refractory to checkpoint inhibitors

Nov 8, 2022

Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Nov 7, 2022

Nouscom's Personalized Neoantigen Cancer Immunotherapy NOUS-PEV Demonstrates Promising Safety, Immunogenicity and Anti-tumor Activity in Solid Tumors

Nov 7, 2022

Wugen to Present Data Characterizing WU-NK-101 at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Nov 7, 2022

Calidi Biotherapeutics Presents Promising Pre-Clinical Data from SuperNova-1 (SNV1), a Novel Oncolytic-Cell Based Platform, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)

Nov 7, 2022

Hummingbird Bioscience Announces Two HMBD-002 Poster Presentations at the Society for Immunotherapy of Cancer 2022 Annual Meeting

Nov 7, 2022

Bicara Therapeutics Presents Preclinical Data for Precision Immunocytokine, BCA356, at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Nov 7, 2022

Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Nov 7, 2022

Therapeutic Solutions International Spin-Off Res Nova Bio Collaborates with Veltmeyer MD Inc. to Provide Breast Cancer Patients Access to Novel Cancer Immunotherapy

Nov 3, 2022

Grid Therapeutics Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Nov 2, 2022

HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Nov 1, 2022

Carisma Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 37th Anniversary Annual Meeting

Nov 1, 2022

AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at World Immunotherapy Congress Europe

Oct 27, 2022

Triumvira Immunologics to Present Clinical and Preclinical Updates at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Oct 27, 2022

Therapeutic Solutions International Announces Launch of Cancer Immunotherapy Spin-Off Res Nova Bio, Inc.

Oct 27, 2022

2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies

Oct 24, 2022

EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy

Oct 21, 2022

Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022

Oct 21, 2022

Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Oct 19, 2022

Avenge Bio to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Oct 19, 2022

Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Oct 18, 2022

Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax™ Immunotherapy Platform

Oct 18, 2022

Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy

Oct 11, 2022

Palleon to Present on Phase 1/2 E-602 Bi-Sialidase Trial Design at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 6, 2022

Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 SITC Meeting

Oct 5, 2022

HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting

Oct 5, 2022

Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies

Sep 29, 2022

Imvax Presents New Data on Personalized Whole-Tumor Derived Immunotherapeutic Platform at 2022 International Cancer Immunotherapy Conference

Sep 28, 2022

Verismo Therapeutics Receives U.S. FDA Orphan Drug Designation for SynKIR-110™, a First-in-Class KIR-CAR T Cell Immunotherapy Candidate, for the Treatment of Mesothelioma

Sep 22, 2022

Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference

Sep 20, 2022

Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR-110™, a KIR-CAR T Cell Immunotherapy Candidate

Sep 16, 2022

Enterome's innovative OncoMimics™-based immunotherapy EO2401 distinguished with 'Best Clinical Research Award' at EANO Meeting 2022 for promising results in recurrent gliobastoma

Sep 16, 2022

EXUMA Biotech to Present at the 2022 Cancer Immunology and Immunotherapy Conference and to Participate in the 7th Annual CAR-TCR Summit

Aug 22, 2022

Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development

Aug 19, 2022

Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110, a KIR-CAR T-cell Immunotherapy Candidate

Aug 17, 2022

Philadelphia-based Biotech Company AUM LifeTech Awarded $400,000 NCI/NIH Grant to Advance Their Lung Cancer Immunotherapy Program Using RNA-Targeting Gene Therapy with Checkpoint Inhibitors

Aug 11, 2022

Nouscom announces leading publication revealing an immune mechanism of action driving anti-tumor activity of adenovirus vectored vaccines and anti-PD1 immunotherapy

Aug 3, 2022

Avenge Bio Announces FDA Clearance of the AVB-001 IND for the Treatment of Ovarian Cancer, a Novel Cellular Therapy Leveraging the LOCOcyte™ Immunotherapy Platform

Jul 19, 2022

Cartography Biosciences Launches to Accelerate Precision Immunotherapy with Comprehensive Antigen Profiling

Jul 18, 2022

Enterome signs major strategic RandD collaboration with Nestlé Health Science to develop and commercialize new AllerMimics™ and EndoMimics™ immunotherapies for food allergies and inflammatory bowel disease

Jul 7, 2022

Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of RandD

Jun 15, 2022

WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

Jun 6, 2022

Nouscom Announces Positive Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

Jun 6, 2022

Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy

Jun 4, 2022

CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Jun 2, 2022

Immunicom Clinical Trial Data at ASCO 2022 Show Immunopheresis LW-02 Column is Safe and Effectively Depletes Soluble TNF-α Receptors in Patients with Advanced Triple Negative Breast Cancer

May 27, 2022

Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

May 24, 2022

Calidi Biotherapeutics Granted U.S. Patent for Proprietary Therapeutic Delivery Platform, Strengthening Company’s Intellectual Property Position in Immunotherapy

May 19, 2022

US FDA accepts Cytovation's IND application for Phase II combination studies of CyPep-1, a first-in-class targeted tumor membrane immunotherapy

May 17, 2022

Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an 'Off-The-Shelf' Cancer Immunotherapy Developed using Nouscom's Proprietary Viral Vector Platform

Apr 25, 2022

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 200 Chinese Patients

Apr 20, 2022

Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1

Apr 13, 2022

Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A

Apr 11, 2022

MiNA Therapeutics Presents Proof of Mechanism Data on MTL-STING as a Novel Cancer Immunotherapy

Apr 8, 2022

Asher Bio to Unveil Two New Immunotherapy Programs, a CD8+ T Cell Targeted IL-21 and a Cis-Targeted IL-2 for Cell Therapy Augmentation, at AACR Annual Meeting

Apr 8, 2022

Imvax Presents New Data on Tumor-Derived Immunotherapies in Glioblastoma, Other Solid Tumors at AACR Annual Meeting 2022

Apr 7, 2022

LTZ Therapeutics Secures $17 Million Pre-Series A Financing for Immunotherapy Development to Treat Cancer and Other Complex Diseases

Apr 5, 2022

Nouscom Announces AACR 2022 Late-Breaking Presentation of Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of MSI-H Solid Tumors

Mar 28, 2022

Ankyra Therapeutics Appoints Howard L. Kaufman, MD as President and Chief Executive Officer

Mar 24, 2022

Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Platform

Mar 15, 2022

Gadeta announces significant progress in advancing pipeline and TEG platform development

Mar 9, 2022

Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at AACR Annual Meeting 2022

Mar 9, 2022

Cellevolve Announces Expansive Global Collaboration with Seattle Children’s Therapeutics to Advance Research for Childhood Brain Cancers

Mar 8, 2022

Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of Lead Glyco-Immunology Drug Candidate for Oncology

Mar 8, 2022

Asher Bio to Showcase Continued Progress with Lead Program AB248 and Growing Pipeline of Precisely-Targeted Immunotherapies at AACR Annual Meeting 2022

Mar 7, 2022

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy USA - English USA - English

Mar 7, 2022

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy USA - English Israel - English

Mar 4, 2022

Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy

Mar 2, 2022

Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer

Mar 1, 2022

Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb

Mar 1, 2022

Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb USA - English USA - Deutsch USA - español USA - Français

Feb 15, 2022

Oxford Finance Announces the Closing of a $50 Million Credit Facility With OncoResponse

Feb 7, 2022

Treos Bio Announces First Patient Dosed in Phase 1b Trial of PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer

Jan 26, 2022

Prokarium Expands RandD Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline

Jan 25, 2022

Cytovation raises $20 million in Series A financing round to advance clinical development of CyPep-1, a first-in-class targeted tumor membrane immunotherapy

Jan 20, 2022

Palleon Pharmaceuticals Announces IND Clearance for First-in-Class Cancer Immunotherapy Leveraging Glyco-Immunology

Jan 10, 2022

BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies

Dec 22, 2021

AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPEAT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China

Dec 15, 2021

Asher Bio Showcases Versatility and Broad Applicability of Cis-Targeting Technology for Precision Immunotherapies at Antibody Engineering Conferences

Dec 1, 2021

IFM Therapeutics Announces Extension of Collaboration Agreement for cGAS-STING Subsidiary, IFM Due

Nov 29, 2021

Turnstone Biologics Announces Research Collaboration with Moffitt Cancer Center to Advance Novel TIL Immunotherapies for Solid Tumor Indications

Nov 29, 2021

Kineta Presents Phase 1/2 Clinical Trial Design of KVA12.1 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Nov 16, 2021

NeoImmuneTech Presents Data in Three Posters at Society for Immunotherapy of Cancer Annual Meeting

Nov 16, 2021

Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe

Nov 16, 2021

Tevogen Bio Announces First Cohort Dosed in Ongoing Proof of Concept Clinical Trial of TVGN-489, its Investigational T cell Immunotherapy Product for Treatment of COVID-19 in High-Risk Patients

Nov 15, 2021

NKGen Biotech Announces Positive SNK01 Clinical Trial Results Presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Nov 15, 2021

PACT Reports New Data Highlighting Predictive Power of Machine Learning Approach Leveraging PACTImmune™ Database at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

Nov 15, 2021

T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T

Nov 12, 2021

Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Nov 12, 2021

Second Genome Presents Preclinical Data at SITC 2021 Demonstrating that a CXCR3-Positive Allosteric Modulator, SG-3-00802, Targets a Key Mechanism Required for Efficacious Immunotherapy

Nov 12, 2021

MiNA Therapeutics Highlights Clinical Data Supporting the Further Development of MTL-CEBPA as an Anti-cancer Immunotherapy

Nov 12, 2021

Grey Wolf Therapeutics Presents Promising Preclinical Data on First-in-Class ERAP1 Inhibitors at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 12, 2021

Bicara Therapeutics Presents Promising New Preclinical Data for Lead Immunotherapy Program BCA101 at the Society for Immunotherapy of Cancer 2021 Annual Meeting

Nov 12, 2021

OncoMyx Presents New Data at SITC 2021 Demonstrating the Potential of a Multi-Armed Myxoma Virus as a Novel Oncolytic Immunotherapy for Solid Tumors and Heme Malignancies

Nov 12, 2021

Asher Bio Announces New Preclinical Data Demonstrating Best-in-Class Potential of AB248, Its Lead Cis-Targeted Il-2 Immunotherapy

Nov 12, 2021

Elicio Therapeutics Presents Preclinical Data on AMP TCR-T and CAR-T Combination Therapies at the 2021 Society for Immunotherapy of Cancer Annual Meeting

Nov 11, 2021

Prokarium Shares Preclinical Proof-of-Concept Data on Its Microbial Immunotherapy Bladder Cancer Program at SITC 2021

Nov 10, 2021

Nouscom to present interim data from Phase 1 trial evaluating NOUS-209, an 'off-the-shelf' neoantigen cancer vaccine for the treatment of MSI-H solid tumors

Nov 10, 2021

Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting

Nov 9, 2021

HotSpot Therapeutics to Present New Data Indicating Successful Targeting of CBL-B at 2021 Society for Immunotherapy of Cancer Annual Meeting

Nov 9, 2021

Immune-Onc Therapeutics to Present Data Supporting Therapeutic Potential of LAIR1 Antagonist Antibodies at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Nov 9, 2021

Strand Therapeutics Awarded Phase I NIH SBIR Contract to Develop mRNA-based CAR-T Immunotherapy for Non-Hodgkin’s Lymphoma

Nov 9, 2021

Vigeo Therapeutics Announces New Phase 1/2 Data from its Expansion Study of VT1021 at the Society for Immunotherapy of Cancer's 2021 Annual Meeting

Nov 9, 2021

Wugen Announces Data Presentation at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Nov 9, 2021

NeoTX Therapeutics to Present at the Society for Immunotherapy of Cancer's 36th Annual Meeting USA - English USA - English

Nov 9, 2021

Istari Oncology Presents Data on Its PVSRIPO Immunotherapy at the Annual November Meetings for the Society for Immunology of Cancer (SITC) and the Society for Neuro-Oncology (SNO)

Nov 9, 2021

MAIA Biotechnology, Inc. Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)

Nov 9, 2021

Codagenix to Present Promising Preclinical Data for Oncolytic Virus Therapeutic CodaLytic™ at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 8, 2021

AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe

Nov 4, 2021

ArsenalBio Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Nov 2, 2021

Immunicom Conference Highlights Innovation in Clinical Trial Design to Advance its Breakthrough Cancer Immunotherapy Platform

Nov 2, 2021

Prokarium Promotes Livija Deban to Chief Scientific Officer to Drive Pipeline Expansion in Cancer Immunotherapy

Nov 2, 2021

OncoResponse Announces Initiation of Phase 1 Trial of OR2805 - Human Monoclonal Antibody Derived from Elite Responder to Cancer Immunotherapy - in Patients with Advanced Cancer

Nov 2, 2021

Shoreline Biosciences Announces $140M Financing To Advance Pipeline Of Next Generation Cell Immunotherapies

Oct 25, 2021

SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company

Oct 21, 2021

Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics

Oct 18, 2021

Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb and Receipt of Milestone Payments Following First Patient Dosing of Two TriNKET™ Immunotherapies USA - English España - español Deutschland - Deutsch France - Français

Oct 18, 2021

Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb and Receipt of Milestone Payments Following First Patient Dosing of Two TriNKET™ Immunotherapies USA - English USA - español USA - Deutsch USA - Français

Oct 14, 2021

Oblique Therapeutics is excited to present the recent progress on its anti-Thioredoxin mAb program at the annual meeting of Society for Immunotherapy of Cancer, Nov 10 - 14, Washington DC, USA

Oct 12, 2021

CG Oncology to Present Two Programs at The Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Oct 8, 2021

OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR Virtual Conference on Tumor Immunology and Immunotherapy

Oct 7, 2021

Kineta Presents Preclinical Data on Its New CD27 Program at the AACR Conference on Tumor Immunology and Immunotherapy

Oct 7, 2021

Immunicom Hires Former FDA Clinician and Medical Device Reviewer to Rapidly Progress Launch of Novel Cancer Immunotherapy

Oct 5, 2021

Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 4, 2021

NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting

Oct 1, 2021

Aleta Biotherapeutics to Present at Society for Immunotherapy of Cancer

Oct 1, 2021

T-knife Therapeutics Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Oct 1, 2021

Vigeo Therapeutics to Present New Phase 1/2 VT1021 Data from its Pancreatic Cancer Expansion Study at the Society for Immunotherapy of Cancer's 2021 Annual Meeting

Sep 30, 2021

OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor Immunology and Immunotherapy

Sep 28, 2021

Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy

Sep 24, 2021

SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19

Sep 22, 2021

CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy CG0070 as Part of Novel Combination for Various Solid Tumor Indications

Sep 14, 2021

Immunicom Presents Promising Preliminary Data from Immunopheresis Studies in Late-Stage Cancer Patients at JCA-AACR 2021

Sep 9, 2021

CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy CG0070 in Combination with OPDIVO (nivolumab) in Metastatic Urothelial Cancer

Aug 30, 2021

Umoja Biopharma Breaks Ground on Extensive Manufacturing Facility for its Next-Generation CAR T Immunotherapies

Aug 18, 2021

Treos Bio Announces FDA Clearance of IND Application for PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer

Aug 10, 2021

Nouscom highlights innovative science behind VENUS, its novel algorithm for identifying and prioritizing patient-specific tumor neoantigens for personalized cancer immunotherapy

Aug 4, 2021

Strand Therapeutics Awarded Two Phase I NIH SBIR Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancer

Aug 4, 2021

Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors

Aug 3, 2021

eTheRNA immunotherapies opens office in Hong Kong to support and build on its growing activities in China and broader Asia-Pacific

Jul 27, 2021

AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

Jul 27, 2021

eTheRNA immunotherapies appoints Mathieu Lane as Chief Financial Officer and President of eTheRNA Inc. located in the U.S.A

Jul 22, 2021

Anocca Raises $47m in a Series B Financing to Advance Its Industrialised Approach to TCR-T Cellular Immunotherapy

Jul 20, 2021

Immunicom’s Data at ASCO Expand on the Antitumor Activity of its Novel Non-Pharmaceutical Immunotherapy in Late-Stage Breast Cancer Patients

Jul 20, 2021

Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy

Jul 13, 2021

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement USA - English USA - English

Jul 12, 2021

Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration To Advance Innovative Immunotherapies

Jul 7, 2021

Treos Bio Enters into Clinical Collaboration to Evaluate its Polypeptide Cancer Immunotherapy PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor

Jul 7, 2021

Adcendo Appoints Michael Pehl as Chief Executive Officer

Jun 29, 2021

eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System

Jun 24, 2021

Kineta's Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTA: A New Immunotherapy Approach to Treating Cancer

Jun 23, 2021

Inotrem Adds a New Strategic Asset to Its Immunotherapy Anti-TREM-1 Drug Pipeline

Jun 22, 2021

SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases

Jun 15, 2021

Umoja Biopharma Closes an Oversubscribed $210 Million Series B Financing to Expand Integrated Immunotherapy Platforms and Advance Programs to the Clinic

Jun 10, 2021

ElevateBio Announces Margo Roberts, Ph.D. Joins as Scientific Advisor for Company’s Immunotherapy Platform Expansion

Jun 10, 2021

Immunicom Presents Promising Clinical Trial Data at AACR in Late-Stage Breast Cancer Patients Treated with Novel Non-Pharmaceutical Immunotherapy

Jun 2, 2021

Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate

Jun 1, 2021

Istari Oncology to Present Data from its PVSRIPO Immunotherapy Platform at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

May 27, 2021

AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology

May 26, 2021

CancerVAX Announces Research Program to Develop Its First Immunotherapy Cancer Treatment

May 19, 2021

Bicara Therapeutics to Present Clinical Data from Lead Immunotherapy Program, BCA101, at the American Society of Clinical Oncology 2021 Annual Meeting

May 12, 2021

Xilio Therapeutics Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at Frontiers in Cancer Immunotherapy Virtual Symposium

May 3, 2021

Synthekine Appoints Internationally Recognized Cancer Immunotherapy Leader Naiyer Rizvi, M.D., as Chief Medical Officer

Apr 21, 2021

Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma

Apr 21, 2021

Immunicom Recognized as One of the Best Places to Work in the U.S.

Apr 20, 2021

Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform

Apr 20, 2021

Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

Apr 20, 2021

Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials

Apr 6, 2021

Hadassah and MyBiotics to Collaborate for the Discovery of Microbiome-Based Therapy for Improving Cancer Immunotherapy USA - English USA - English

Apr 1, 2021

KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy USA - English USA - English

Apr 1, 2021

KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy

Mar 30, 2021

Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors

Mar 25, 2021

Istari Oncology Announces Publication of Data Showing the Investigational Immunotherapy PVSRIPO Leads to Robust, Functional T Cells—Critical for Antitumor Immunity

Mar 24, 2021

Enterome Receives FDA IND Clearance for EO2463, an 'OncoMimic' based Immunotherapy Targeting Liquid Tumors

Mar 23, 2021

Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology

Mar 23, 2021

Asher Bio Launches with $55 Million Series A Financing Led by Third Rock Ventures to Discover and Develop Highly Specific Immunotherapies Using a Novel Technology Platform

Mar 22, 2021

Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million

Mar 15, 2021

Bicara Therapeutics Launches with Deep Pipeline of First-in-Class Dual Action Biologics for Cancer Immunotherapy

Mar 11, 2021

Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy

Mar 9, 2021

ImmunityBio and NantKwest Complete Merger

Mar 4, 2021

DNAtrix Announces First Patient Dosed in Clinical Study of DNX-2440, an OX40 Ligand Expressing Immunotherapy, in Colorectal Cancer and Other Cancers with Liver Metastasis

Mar 4, 2021

ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases

Mar 3, 2021

Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs

Mar 2, 2021

Akoya and Johns Hopkins’ Collaborative Agreement Supports Pioneering New Approach to Immunotherapy Biomarker Discovery and Validation

Mar 1, 2021

CytoImmune Therapeutics Establishes Operations in Puerto Rico to Develop Novel Cancer Immunotherapy Products

Feb 23, 2021

Intrommune Therapeutics Publishes Peanut Allergy and Immunotherapy Report

Feb 10, 2021

Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies

Jan 28, 2021

ImmunityBio Announces Positive Phase 2 Results Showing That Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer

Jan 25, 2021

Immunicom Makes StartUpCity’s Global “Ten Most Promising 2020 Biotech Startups”

Jan 25, 2021

Notch Therapeutics Appoints Cellular Immunotherapy Veteran Chris Bond, Ph.D. as SVP, Preclinical and Translational Sciences

Jan 18, 2021

Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Officer

Jan 13, 2021

NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials

Jan 12, 2021

Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate USA - English España - español France - Français Deutschland - Deutsch

Jan 12, 2021

Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET Immunotherapy Drug Candidate USA - English España - español France - Français Deutschland - Deutsch

Jan 12, 2021

DIACCURATE acquires BIOKINESIS to create a sole-in-class biotech player in oncology and immunotherapy

Jan 12, 2021

Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate USA - English USA - español USA - Français USA - Deutsch

Jan 11, 2021

Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform

Jan 7, 2021

CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies

Dec 21, 2020

ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company

Dec 18, 2020

Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform

Dec 8, 2020

Candel Therapeutics Appoints Pharma Veteran and Immunologist Paul-Peter Tak, M.D., Ph.D., as Chief Executive Officer; Expands Leadership Team With Chief Financial Officer, Chief Business Officer and Chief Regulatory Officer Appointments

Dec 6, 2020

ElevateBio’s HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting

Dec 1, 2020

Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients with Solid Tumors

Dec 1, 2020

Calidi Biotherapeutics Announces European Patent Granted by EPO: Combination Immunotherapy Approach for Treatment of Cancer

Dec 1, 2020

Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer

Dec 1, 2020

Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients with Solid Tumors USA - English USA - español USA - Français USA - Deutsch

Nov 18, 2020

Umoja Biopharma Launches with $53M Series A Financing to Develop Fully Integrated, Scalable, In Vivo Immunotherapy Platform

Nov 12, 2020

CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 in Combination with OPDIVO (nivolumab) in Muscle-Invasive Bladder Cancer

Nov 10, 2020

Bolt Biotherapeutics Presents BDC-1001 Ongoing Clinical Trial Design and Supportive Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting

Nov 10, 2020

Xilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 9, 2020

Apexigen Announces First Preclinical Data Presentations On Novel Anti-TNFR2 And Anti-SIRPα Antibody Programs At The 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 9, 2020

Sensei Biotherapeutics Presents Additional Data from Phase 1/2 Clinical Trial of SNS-301 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 9, 2020

Apexigen Announces First Preclinical Data Presentations On Novel Anti-TNFR2 And Anti-SIRPalpha Antibody Programs At The 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 9, 2020

Istari Oncology Presents Positive Data from Phase 1 Study of PVSRIPO in Patients with Unresectable Treatment Refractory Melanoma at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Nov 9, 2020

Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting

Nov 9, 2020

Silverback Therapeutics to Present Data on Two Programs at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting

Nov 9, 2020

Cygnal Therapeutics to Present Poster at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Nov 9, 2020

OncoMyx Announces Presentation of Preclinical Efficacy Data of Novel Oncolytic Immunotherapy at SITC 2020

Nov 9, 2020

Kleo Pharmaceuticals Presents Preclinical Proof-of-Concept Data on a Novel Chemical Conjugation Platform (MATE™) at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting

Nov 6, 2020

Memo Therapeutics AG Raises CHF 14 Million in a Series B Financing Round

Nov 4, 2020

XNK Therapeutics receives US orphan drug status for NK cell-based immunotherapy in multiple myeloma

Nov 2, 2020

AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy

Nov 2, 2020

Immunomic Therapeutics to Present at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting and Pre-Conference Programs

Oct 29, 2020

Worldwide Dendritic Cell Cancer Vaccine Immunotherapy Industry to 2026 - Featuring 3M, Activartis and Argos Therapeutics Among Others

Oct 27, 2020

Prokarium Closes $21M Series B Financing Round and Strengthens Board

Oct 20, 2020

WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs) Data Selected for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Oct 20, 2020

Kineta Presents New Preclinical Data on its VISTA Antagonist Antibodies at the American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy

Oct 19, 2020

OncoMyx Announces Presentation of Preclinical Data for Novel Oncolytic Virotherapy at AACR Tumor Immunology and Immunotherapy Virtual Conference

Oct 19, 2020

Dr. Sid Kerkar Joins EXUMA Biotech as Vice President Oncology, RandD, Company Presents Data on HER2-Targeting CAR-T at AACR Tumor Immunology and Immunotherapy Conference

Oct 14, 2020

ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

Oct 13, 2020

CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Expanded Phase 2 Study of Pancreatic Cancer Treatment

Oct 6, 2020

First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma

Sep 23, 2020

OncoImmune Launches First-in-human Clinical Trial for ONC-392 – The anti-CTLA-4 Antibody that Preserves CTLA4 Recycling for Safer and More Effective Immunotherapy

Sep 18, 2020

Phosplatin Therapeutics Announces Results from Phase 1b Dose Escalation Study of PT-112 Plus Avelumab in Patients with Solid Tumors

Sep 15, 2020

Transcenta Successfully Scaled up the Continuous Perfusion Process and Completed GMP Manufacturing of a Novel Bispecific Antibody for Cancer Immunotherapy

Sep 14, 2020

LAVA Therapeutics, Amsterdam UMC and Monash University Announce Publication of a Novel Cancer Immunotherapy Approach in Nature Cancer

Sep 9, 2020

Enterome - First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative 'OncoMimic' based Immunotherapy Candidate Targeting Adrenal Tumors

Aug 17, 2020

Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program

Aug 17, 2020

HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium in the Fight Against COVID-19

Aug 10, 2020

Dragonfly Therapeutics Announces BMS Opt-In of Fourth TriNKET™ Immunotherapy Drug Candidate English español Français Deutsch

Aug 10, 2020

Dragonfly Therapeutics Announces BMS Opt-In of Fourth TriNKET™ Immunotherapy Drug Candidate USA - English USA - Français USA - Deutsch USA - español USA - Nederlands

Aug 6, 2020

ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Novel Intratumoral Oncolytic Virus Immunotherapies

Aug 4, 2020

7 Hills Pharma Awarded Pioneering Patent Estate Covering Integrin Activators to Improve Effectiveness of Immunotherapies

Jul 30, 2020

Enterome initiates first clinical trial with EO2401 - an innovative microbiome-antigen ('OncoMimic') based cancer immunotherapy candidate targeting aggressive brain cancer

Jul 27, 2020

CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy

Jul 21, 2020

Dragonfly Therapeutics Initiates Phase 1/2 Study of its IL12 Immunotherapy in Patients with Advanced Solid Tumors English español Nederlands Deutsch Italiano Français

Jul 21, 2020

Dragonfly Therapeutics Initiates Phase 1/2 Study of its IL12 Immunotherapy in Patients with Advanced Solid Tumors USA - English USA - español USA - Nederlands USA - Deutsch USA - Italiano USA - Français

Jul 16, 2020

Oncorus Initiates First-in-Human Phase 1 Study of ONCR-177 for the Treatment of Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors

Jun 24, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)

Jun 18, 2020

CatalYm to Present Data on Targeting Novel Checkpoint GDF-15 for Immunotherapy of Cancer at the AACR Annual Meeting 2020

Jun 2, 2020

First Patient Treated in Phase 1 Clinical Trial Of Incysus Therapeutics Gamma Delta (γδ) T Cell Immunotherapy for Patients With Newly Diagnosed Glioblastoma

May 30, 2020

NKMax America To Present Data from its Natural Killer Cell Immunotherapy Clinical Program at the ASCO20 Virtual Scientific Program

May 29, 2020

Treos Bio Reports Positive Final Results of Phase I/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster Presentation

May 27, 2020

Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers

May 15, 2020

HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise to Be Precision Immunotherapies for Cancer Patients

May 14, 2020

NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer

May 12, 2020

Incysus Therapeutics Treats First Patient in Phase 1 Study of Gamma Delta (γδ) T Cell Immunotherapy in Leukemia and Lymphoma Patients Undergoing Allogeneic Stem Cell Transplantation

May 11, 2020

Portage Makes Additional Investment in Stimunity S.A.S, a Paris-Based Cancer Immunotherapy Company.

Apr 27, 2020

Actym Therapeutics Raises $34 Million Series A

Apr 23, 2020

Affinivax Announces $120 Million Series B Financing to Advance Pipeline of Novel MAPS Vaccines and Immunotherapies

Mar 26, 2020

First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy

Mar 24, 2020

Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing for TAC T-Cell Therapeutic Targeting Solid Tumors

Mar 2, 2020

Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases

Feb 5, 2020

WindMIL Therapeutics Announces Cancer Immunotherapy Pre-Clinical Research Collaboration with University of Pennsylvania

Feb 4, 2020

AIVITA Biomedical Completes Patient Recruitment in Phase 2 GBM Trial

Feb 3, 2020

Survey Confirms Physician Interest in Peanut Allergy Immunotherapy

Jan 9, 2020

Immuneering Strengthens Executive Team With Appointment of Howard L. Kaufman, M.D., as Head of Research and Development

Jan 9, 2020

Bolt Biotherapeutics Expands Scientific Advisory Board with Appointment of Dr. Priti Hegde

Jan 8, 2020

Adagene Completes $69 Million Series D Financing Led by Growth Investor General Atlantic

Jan 6, 2020

CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma

Dec 19, 2019

Turnstone Biologics Announces Global Collaboration and License Agreement with Takeda to Develop Novel Viral Immunotherapies

Dec 16, 2019

NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS

Dec 10, 2019

ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials

Nov 19, 2019

Torque Presents Preclinical Data for Lead Deep-Primed Cellular Immunotherapy Programs at AACR 2019 Special Conference on Tumor Immunology and Immunotherapy

Nov 18, 2019

AgilVax to Present Positive Preclinical Data for Monoclonal Antibody Targeting xCT at the American Association for Cancer Research’s Tumor Immunology and Immunotherapy Conference

Nov 13, 2019

EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform

Nov 13, 2019

Dragonfly Therapeutics Announces Celgene Opt-In of Third TriNKET™ Immunotherapy Drug Candidate

Nov 13, 2019

Dragonfly Therapeutics Announces Celgene Opt-In of Third TriNKET™ Immunotherapy Drug Candidate USA - English USA - Français USA - español USA - Deutsch

Nov 8, 2019

Kymab Presents Update on Lead Immunocytokine Program KY1043 at Society of Immunotherapy for Cancer 34th Annual Meeting

Nov 8, 2019

Torque Presents New Preclinical Data for Three Deep-Primed Cellular Immunotherapy Programs, Including Newly Unveiled Deep TLR, at SITC 2019 Meeting

Nov 8, 2019

Actym Therapeutics Will Present Data at the 2019 Society for the Immunotherapy of Cancer (SITC) Annual Meeting

Nov 8, 2019

Tempest Therapeutics’ Oncology Programs Presented at Society of Immunotherapy for Cancer Annual Meeting

Nov 7, 2019

Palleon Pharmaceuticals to Present Preclinical Data on EAGLE and HYDRA Platforms at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

Nov 7, 2019

Treos Bio Presents Positive Data on Its Off-the-Shelf Shared Antigen-Based Cancer Vaccine Against Microsatellite-stable metastatic colorectal cancer and Personalized Vaccines Against Three Metastatic cancers

Nov 7, 2019

Enterome Enters Research Collaboration With Major Cancer Center Focused on New Microbiome-derived Immunotherapies

Nov 6, 2019

ALX Oncology Presents Clinical Biomarker Data from ALX148 Clinical Trial Solid Tumor Combination Cohorts at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 6, 2019

Ervaxx Launches to Pioneer the Use of Dark Antigens™ for the Development of Off-the-Shelf Cancer Vaccines and T-cell Receptor-based Immunotherapies

Nov 6, 2019

Primmune Therapeutics Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 5, 2019

WindMIL Therapeutics to Present Data Demonstrating Marrow-Infiltrating Lymphocytes’ (MILs™) Superior Functionality Compared to Peripheral Blood Counterparts at 34th Annual Meeting of the Society for Immunotherapy of Cancer

Nov 5, 2019

Checkmate Pharmaceuticals Presents Positive Clinical Data with CMP-001 at The 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC)

Nov 5, 2019

EpicentRx Initiates Dosing in Phase 3 Trial of Immunotherapy RRx-001 for Third-line Small Cell Lung Cancer

Nov 5, 2019

Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study

Nov 5, 2019

Bolt Biotherapeutics Announces ISAC Data Presentation At the Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 4, 2019

NeoTX Therapeutics to Present at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

Nov 1, 2019

Checkmate Pharmaceuticals Announces Data Presentations for Lead Program at The 34th Annual Meeting of The Society for Immunotherapy of Cancer

Oct 31, 2019

Eureka Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Oct 31, 2019

SQZ Biotech to Present New Data at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

Oct 30, 2019

AIVITA Biomedical Announces Publication Detailing Immune Mechanisms Leading to Complete Remission of Measurable Metastatic Melanoma in Patient Treated with AIVITA Immunotherapy

Oct 23, 2019

EpiVax Oncology Announces Three Abstracts Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019)

Oct 22, 2019

Nurix Therapeutics Announces Upcoming Scientific Presentation for its CBL-B Program at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

Oct 17, 2019

AIVITA Biomedical Announces Publication Comparing Clinical Outcomes in Patients Treated with AIVITA's Immunotherapy and Other Immunotherapies

Oct 8, 2019

Bolt Biotherapeutics Announces Scientific Advisory Board with the Appointment of Drs. Larry Fong, Roy Herbst and Bruce Roth

Oct 2, 2019

ALX Oncology to Present ALX148 Clinical Biomarker Data at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 2, 2019

AIVITA Biomedical Announces Publication Concerning a Predictive Biomarker for Melanoma Patients Treated with the Company's Platform Immunotherapy

Oct 1, 2019

Immunomic Therapeutics Assumes Sponsorship of ATTAC-II IND for ITI-1000, a Dendritic Cell Vaccine in Phase 2 for the Treatment of GBM

Oct 1, 2019

ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research Center

Oct 1, 2019

Numab and Eisai Enter Into a Global Research and Option Agreement to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

Sep 16, 2019

Intrommune Therapeutics Supports Outcome of FDA Allergenic Product Advisory Committee Vote

Sep 4, 2019

Bolt Biotherapeutics Appoints Veteran Executive Randall Schatzman as CEO to Lead the Next Phase of Growth

Aug 21, 2019

Intrommune Therapeutics Receives Formulation Patent Notice of Allowance

Aug 14, 2019

Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical's Phase 2 Clinical Trial

Aug 12, 2019

TScan Therapeutics Announces Pioneering Publication in Scientific Journal Cell Describing New Methods to Identify Targets for T Cell Receptor Immunotherapy

Aug 6, 2019

Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Pioneer to its Scientific Advisory Board

Aug 6, 2019

Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Pioneer to its Scientific Advisory Board India - English USA - English

Aug 1, 2019

ImCheck Therapeutics Awarded €2 Million From Bpifrance to Advance its First-in-class Immunotherapy Program Into the Clinic

Jul 26, 2019

Xynomic Pharma Will Present at 3rd World-China Immunotherapy & Gene Therapy Congress

Jul 26, 2019

Xynomic Pharma Will Present at 3rd World-China Immunotherapy and Gene Therapy Congress

Jul 24, 2019

TScan Therapeutics Formed to Overcome Challenges of Current Immunotherapies with Novel TCR Discovery Platform and $48 Million in Funding

Jul 10, 2019

Geneos Therapeutics Announces First Patient Dosed with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology

Jul 9, 2019

Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology

Jul 9, 2019

Be The Match BioTherapies® and Tmunity Announce Collaboration to Support Clinical Trials of Next-Generation Immunotherapies

Jul 9, 2019

Be The Match BioTherapies and Tmunity Announce Collaboration to Support Clinical Trials of Next-Generation Immunotherapies

Jun 27, 2019

Vycellix Founders Awarded Innovation Grant by Sweden’s Vinnova to Establish New World-Class Research Environment on Development of Next-Generation Natural Killer Cell-based Cancer Immunotherapy

Jun 19, 2019

Incysus Therapeutics Announces Publication of U.S. Patent for Drug Resistant Immunotherapy (DRI) Technology

Jun 18, 2019

FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501

Jun 4, 2019

Strand Therapeutics Announces $6 Million Seed Financing to Advance its Programmable mRNA Therapeutics Platform

Jun 3, 2019

Dr. Soon-Shiong to Launch ImmunityBio, an Immunotherapy Company at Upcoming Jefferies 2019 Annual Healthcare Conference

May 29, 2019

MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

May 29, 2019

Vor Biopharma Announces Publication of Proof-of-Concept Study of its Lead Program in the Scientific Journal Proceedings of the National Academy of Sciences

May 29, 2019

Multiple Myeloma Research Foundation (MMRF) Venture Philanthropy Fund Invests in NexImmune to Advance Novel Immunotherapy Candidate Into Clinical Trials

May 15, 2019

IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win® Immunotherapy in Non-small Cell Lung Cancer

May 14, 2019

Intensity Therapeutics to Present Data on Intratumoral Injection of INT230-6 at the Frontiers in Cancer Immunotherapy Symposium

May 9, 2019

EnGeneIC Announces First Patients with Advanced-Stage Pancreatic Cancer Dosed in Phase 1/2a Clinical Study of Targeted Cytotoxic Immunotherapy

May 1, 2019

CStone and Numab announce exclusive regional licensing agreement for ND021, a multi-functional drug candidate and potential next-generation immunotherapy

Apr 16, 2019

Frank Malinoski, MD, PhD, joins Affinivax as Senior Vice President of Clinical Development and Regulatory Affairs

Apr 1, 2019

Torque Presents New Preclinical Data for its Deep-Primed Cellular Immunotherapy Programs at the American Association for Cancer Research (AACR) Annual Meeting

Mar 27, 2019

Enterome to Present Data on Its Innovative Microbiome-derived Molecular Mimicry Approach to Cancer Immunotherapy at AACR 2019

Mar 26, 2019

Akrevia Therapeutics Licenses Exclusive Rights from City of Hope to Expand Development Pipeline of Potent, Tumor Targeted Immunotherapies

Mar 26, 2019

Abcuro Announces Pre-Clinical Data on New Immuno-Oncology Target

Mar 25, 2019

Portage makes additional investment in Stimunity S.A, a Paris-based cancer immunotherapy company.

Mar 20, 2019

Enterome Announces Research Collaboration with Renowned US Cancer Institute Focused on New Microbiome-derived Cancer Immunotherapy

Mar 18, 2019

Cytovation Initiates Clinical Development Programme With CyPep-1, a First-in-class Lytic Agent for Tumor Immunotherapy

Mar 14, 2019

Targovax Grants Zelluna Immunotherapy an FTO License to Intellectual Property Relating to Mutant Ras T Cell Receptor Technology

Mar 8, 2019

Intrommune Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy for Food Allergy

Feb 27, 2019

First Clinical Results Evaluating Allogeneic, Off-The-Shelf, Placental-Derived Cells to be Presented by Celularity at 2019 AACR Annual Meeting

Feb 21, 2019

Cell and Gene Immunotherapy Biotech, Vycellix, to Establish Headquarters in Tampa

Feb 21, 2019

Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies

Feb 4, 2019

Torque and Thermo Fisher Scientific Announce Collaboration to Build State-of-the-Art Facility to Manufacture Torque's Deep-Primed T Cell Immunotherapies

Jan 16, 2019

AIVITA Biomedical Receives IND Clearance for Phase 1B Melanoma Trial

Jan 3, 2019

AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39

Jan 3, 2019

Gamma-Delta T Cell Immunotherapy Pioneer, Lawrence Lamb, PhD, to Join Incysus Therapeutics as Chief Scientific Officer

Dec 17, 2018

Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies

Dec 13, 2018

Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET™ Immunotherapy Drug Candidates

Dec 13, 2018

Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET™ Immunotherapy Drug Candidates USA - English USA - Français USA - Deutsch USA - español

Dec 4, 2018

Generon Presented Pre-Clinical Immunotherapy Results With CD3-Activating Bi-Specific Antibody Targeting CD19 on B Cells in Mono- and Bi-Valent Format

Nov 30, 2018

Turnstone Biologics Unveils Novel Vaccinia Oncolytic Viral Immunotherapy Platform

Nov 28, 2018

Vor Biopharma Announces Issuance of Foundational U.S. Patent Broadly Covering Compositions and Methods to Treat Hematologic Malignancies

Nov 27, 2018

Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy

Nov 26, 2018

Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the AACR Special Conference on Tumor Immunology and Immunotherapy

Nov 26, 2018

Alcyone Lifesciences Announces the Use of AMC Intratumoral Delivery Platform in the Treatment of First Patient in DNX-2440 Glioblastoma Trial

Nov 22, 2018

Vineti™ to Partner With Tessa Therapeutics™ to Advance and Scale Cancer Immunotherapies World-Wide

Nov 15, 2018

PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy on Virus-Based Gene Therapy to Treat Solid Tumors

Nov 15, 2018

Immunomic Therapeutics to Present at the 2018 World Vaccine & Immunotherapy Congress

Nov 15, 2018

Immunomic Therapeutics to Present at the 2018 World Vaccine and Immunotherapy Congress

Nov 13, 2018

Kleo Pharmaceuticals Secures $21 Million to Advance Novel Small Molecule Cancer Immunotherapies

Nov 13, 2018

First stage of Qu Biologics’ clinical trial assessing mucosal healing for novel immunotherapy for Crohn’s disease reaches 50% enrolment

Nov 13, 2018

United Neuroscience Strengthens Vaccine Pipeline with Novel Immunotherapy for Parkinson's Disease

Nov 12, 2018

Torque Presents Preclinical Data for Deep IL-15 Primed T Cells, Deep IL-12 Primed T Cells, and for the Slipstream™ Process for Manufacturing These First-in-Class, Multi-Target Cellular Immunotherapies

Nov 9, 2018

GigaGen to Present Data on Immuno-Oncology Pipeline at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

Nov 8, 2018

Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting

Nov 8, 2018

Actym Therapeutics Will Present Data at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 8, 2018

ADC Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

Nov 8, 2018

ADC Therapeutics kündigt Präsentationen auf der 33. Jahrestagung der Society for Immunotherapy of Cancer (SITC) an

Nov 8, 2018

ADC Therapeutics annonce des présentations à la 33e conférence annuelle de la Society for Immunotherapy of Cancer (SITC)

Nov 8, 2018

Intensity Therapeutics Highlights INT230-6 Data in Advanced Solid Tumors at Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

Nov 7, 2018

AIVITA Biomedical to Exhibit ROOT OF CANCER Immunotherapy at 33rd SITC Annual Meeting

Nov 7, 2018

ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors

Nov 7, 2018

Effectiveness of DNAtrix's DNX-2440 Oncolytic Virus Expressing OX40L in Solid Tumors to be Presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer

Nov 7, 2018

CureVac to Present Preliminary Phase I Data on CV8102, an Intratumoral RNA-based Cancer Therapy, at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

Nov 7, 2018

Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics

Nov 6, 2018

Compass Therapeutics Announces Preclinical Data on Lead Antibody Program and NK Cell Engager Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting

Nov 6, 2018

Codiak BioSciences Presents First Data on exoSTING - A Novel Engineered Exosome Therapeutic Targeting Checkpoint Refractory Tumors at the Society for Immunotherapy of Cancer's 33rd Annual Meeting

Nov 6, 2018

Sensei Biotherapeutics Presents Clinical Trial Data Demonstrating SNS-301 Induces Rapid and Robust Antigen-specific Immune Responses at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

Nov 6, 2018

Atreca to Present Data Further Demonstrating Ability of the Company’s Discovery Engine to Identify Patient-Derived Antibodies that Target Non-Autologous Tumor Tissue

Nov 6, 2018

Vedanta Biosciences Announces Preclinical Data on Microbiome-Derived Immuno-Oncology Candidate

Nov 6, 2018

Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

Nov 2, 2018

Torque Announces Appointment of Immunotherapy Pioneer F. Stephen Hodi, MD, to Scientific Advisory Board and Alex Bruni as COO/ CFO

Oct 23, 2018

Integral Molecular Receives NIAID Award to Combat COVID-19

Oct 23, 2018

enGene Receives Funding Through Cystic Fibrosis Foundation's Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis

Oct 23, 2018

Gain Therapeutics Files Registration Statement with SEC for Proposed Initial Public Offering

Oct 19, 2018

Sensei Biotherapeutics Reports Results from Phase 1 Clinical Trial of SNS-301, a First-in-Class Cancer Immunotherapy Targeting ASPH, a Novel Tumor-Specific Antigen

Oct 10, 2018

AUM LifeTech, CHOP and Penn Partnering to Advance Cancer Immunotherapy Against Lung Cancer Using Foxp3 Gene Silencing FANA ASO Therapy

Oct 9, 2018

Sensei Biotherapeutics to Present Clinical Data at Upcoming Oncology Medical Conferences

Oct 8, 2018

Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Experts to its Scientific Advisory Board

Oct 8, 2018

eTheRNA Opens State-of-the-art Manufacturing Facility in Belgium to Support the Development of its TriMix-based mRNA Cancer Immunotherapies

Oct 8, 2018

Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Experts to its Scientific Advisory Board USA - English USA - Français USA - Deutsch USA - español

Oct 1, 2018

Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors

Oct 1, 2018

Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors USA - English USA - Deutsch USA - español USA - Français

Sep 24, 2018

Batu Biologics Announces the Release of the Starve The Tumor Immunotherapy Blog

Sep 20, 2018

Numab Appoints Immunotherapy Pioneer Ignacio Melero as Scientific Advisor

Sep 5, 2018

Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate Combination Therapy with CMP-001 and Avelumab

Sep 4, 2018

Turnstone Biologics and the La Jolla Institute for Allergy and Immunology Enter into Strategic Collaboration for Personalized Neoantigen Immunotherapies

Aug 20, 2018

Batu Biologics Identifies Gene Types Associated with Response to ValloVax

Jul 26, 2018

Batu Biologics Files Patent on Patient Selection for Right to Try Law

Jun 28, 2018

Kymab Announces Agreement to Evaluate KY1044, its Novel Antibody Targeting ICOS, and Anti-PD-L1 Immunotherapy for testing in Multiple Solid Tumors

Jun 27, 2018

Carisma Therapeutics Announces a $53 Million Series A Financing to Develop Novel CAR Macrophage Cellular Immunotherapy

Jun 20, 2018

AIVITA Biomedical Announces U.S. Food and Drug Administration Clearance of IND for Phase II Glioblastoma Multiforme Trial

Jun 5, 2018

Sensei Biotherapeutics Reports New Data from Phase 1 Clinical Trial of SNS-301

Jun 5, 2018

Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B

Jun 4, 2018

Portage provides update on its associate, Stimunity S.A, a Paris-based cancer immunotherapy company

May 30, 2018

APEIRON to Present Clinical Data on Two Immunotherapy Programs at the 2018 ASCO Annual Meeting

May 24, 2018

Checkmate Pharmaceuticals Announces Start of Phase 1b Trial of CMP-001 in Combination with Anti-PD-L1 Immunotherapy in Anti-PD-1/PD-L1 Resistant Advanced Non-Small Cell Lung Cancer

May 24, 2018

eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-Based Cancer Specific Immunotherapy (ECI-006) in Melanoma

May 21, 2018

MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM Immunotherapy for the Treatment of Newly Diagnosed Glioblastoma

May 16, 2018

Turnstone Biologics Announces U.S. FDA Acceptance of IND for Immunotherapy Targeting HPV Positive Cancers

May 15, 2018

MimiVax to Present Interim Phase II Trial Data on Multi-focal Immunotherapy SurVaxM for the Treatment of Glioblastoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

May 15, 2018

Intrommune Therapeutics Submits Pre-IND Meeting Request to the U.S. FDA for INT301, Its Peanut Allergy Oral Mucosal Immunotherapy Drug Candidate, During Food Allergy Awareness Week

May 14, 2018

Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

May 14, 2018

Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 2, 2018

Triumvira Immunologics Announces Strategic Relationship for GMP Manufacturing with Centre for Commercialisation of Cancer Immunotherapy

Apr 27, 2018

PhoreMost and NeoPhore Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme

Mar 22, 2018

Kineta Immuno-Oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference

Mar 19, 2018

eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma

Mar 15, 2018

Batu Biologics Chief Executive Officer Samuel Wagner to Moderate Congressional Immunotherapy Symposium

Feb 27, 2018

ABL Europe Enters into a Collaboration for the GMP Manufacture of Hookipa Biotech's Heterologous Viral Vector Immunotherapy Platform

Feb 27, 2018

Quentis Therapeutics Debuts with $48 Million Series A Financing to Advance First-in-Class Immunotherapies Targeting Endoplasmic Reticulum Stress Response Pathways

Feb 13, 2018

Incysus Presents Positive Data on Drug-Resistant Immunotherapy for Glioblastoma at AACR CNS Immunotherapy Conference

Feb 5, 2018

Tessa Therapeutics Announces Opening of Recruitment Sites Across the United States for its Phase III Nasopharyngeal Cancer Immunotherapy Trial

Jan 29, 2018

Pioneer in Taking Immunotherapies Through the Clinic Joins Dragonfly Therapeutics as Chief Medical Officer

Jan 23, 2018

Tmunity Therapeutics Raises $100 Million in Series A Financing to Advance Portfolio of Next-Generation T cell Immunotherapies to Transform the Treatment of Cancer

Jan 23, 2018

Be The Match BioTherapies Invests in Tmunity Therapeutics to Support Advancement of Next-Generation T cell Immunotherapies

Jan 19, 2018

Atreca to Participate in Immunotherapy Showcase at the 2018 Precision Medicine World Conference

Jan 3, 2018

Elstar Therapeutics Closes $39M Series A Financing to Support Development of its Universal Targeted Immunotherapy Platform

Jan 2, 2018

NexImmune Raises $23 Million to Advance Endogenous Cellular ImmunoTherapy into Clinical Development

Dec 19, 2017

Tessa Therapeutics Closes USD 80 Million Financing Round Led by Temasek

Dec 5, 2017

New Scientific Publication Supports Agilvax’s Novel Immunotherapy Development for Metastatic Breast Cancer

Nov 29, 2017

Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy

Nov 28, 2017

Biothera Pharmaceuticals Enters Cancer Immunotherapy Clinical Trial Collaboration Agreement

Nov 27, 2017

Medeor Therapeutics Raises $57 Million In Series B Financing

Nov 14, 2017

OncoQuest Announces Presentation of Pre-Clinical Data from its IgE Based Immunotherapy Platform Technology at the 32nd Annual Society for Immunotherapy of Cancer (SITC)

Nov 14, 2017

ImmusanT Raises $40 Million in Series C Financing

Nov 13, 2017

NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in Preclinical Model

Nov 13, 2017

DNAtrix Virus Expressing T-Cell Co-stimulator OX40L (CD252) Presented at the 2017 Society for Immunotherapy of Cancer Meeting

Nov 10, 2017

Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma

Nov 9, 2017

ImmunoMolecular Therapeutics Launches to Advance Innovative Immunotherapies for Genetically Defined Type 1 Diabetes and Other Autoimmune Diseases

Nov 8, 2017

Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

Nov 7, 2017

Lycera Presents Tumor Selection Rationale for Phase 2a Study at Society for Immunotherapy of Cancer's (SITC) 2017 Annual Meeting for RORgamma Agonist, LYC-55716

Nov 7, 2017

Pique Therapeutics Announces Positive Results in Phase 2 Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer

Nov 7, 2017

Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed Cancer

Nov 6, 2017

NousCom Raises €42 Million Series B Financing

Nov 1, 2017

Vedanta Biosciences to Advance Cancer Immunotherapy Candidates Based on Microbiome-Derived Live Biotherapeutics that Induce CD8+ T Cells

Oct 31, 2017

Apexigen Announces Late-Breaking Oral Presentation for Immune Activating Antibody APX005M at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 31, 2017

Vedantra Pharmaceuticals Extends Research Collaboration with Neon Therapeutics to Develop Novel Cancer Immunotherapies

Oct 31, 2017

Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

Oct 30, 2017

CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics

Oct 26, 2017

Madison Vaccines Incorporated Appoints Jeff Bailey to Its Board of Directors

Oct 10, 2017

AbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology

Oct 5, 2017

WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based on Marrow-Infiltrating Lymphocytes

Oct 5, 2017

Alexo Therapeutics to Present ALX148 Clinical Data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Sep 29, 2017

Siamab Therapeutics Presented New Data for its Anti-STn Antibody Therapeutics Showing Myeloid-Derived Suppressor Cells as a Promising Cancer Immunotherapy Target at Cambridge Healthtech Institute’s Targeting Tumor Myeloid Cells Conference

Sep 25, 2017

eTheRNA immunotherapies Awarded €1 Million Grant From Flanders Innovation and Entrepreneurship to Further Upgrade its State-of-the-art Production Process for TriMix mRNA Immunotherapies

Sep 25, 2017

EpiVax Launches Precision Cancer Immunotherapy Venture, EpiVax Oncology Deutschland - Deutsch USA - English España - español

Sep 18, 2017

Immunocore and the Bill and Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases

Sep 18, 2017

Formula Pharmaceuticals Announces Initiation of the First Clinical Trial for Allogeneic CIK-CAR Cancer Immunotherapy

Sep 13, 2017

CrownBio’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer

Aug 17, 2017

Atreca Completes Oversubscribed $35 Million Series B Financing to Advance Novel Cancer Immunotherapies

Jul 18, 2017

PeptiDream and Kleo Pharmaceuticals Announce Collaboration Agreement to Develop Novel Immunotherapies for Oncology

Jun 30, 2017

eTheRNA Immunotherapies Advances In-Vivo mRNA Cancer Immunotherapy into First Oncology Clinical Studies

Jun 20, 2017

Cell Medica Acquires WT1 Cancer Immunotherapy from Cell and Gene Therapy Catapult

Jun 19, 2017

Tessa Therapeutics and Parker Institute for Cancer Immunotherapy Enter into Strategic Alliance Agreement

Jun 12, 2017

Dragonfly Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel Natural Killer (NK) Cell-Based Immunotherapies using Dragonfly's TriNKET™ technology platform

Jun 12, 2017

Immunomic Therapeutics, Inc. to Participate in Webcast on Making a Name in Cancer Immunotherapy

Jun 12, 2017

Dragonfly Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel Natural Killer (NK) Cell-Based Immunotherapies using Dragonfly's TriNKET™ technology platform España - español Deutschland - Deutsch France - Français USA - English

May 31, 2017

Atreca, Inc., and Dana-Farber Cancer Institute Establish Broad Cancer Immunotherapy R&D Collaboration

May 31, 2017

Atreca, Inc., and Dana-Farber Cancer Institute Establish Broad Cancer Immunotherapy RandD Collaboration

May 23, 2017

Dragonfly Therapeutics Adds Natural Killer Cell-Based Cancer Immunotherapy Expert to Its Scientific Advisory Board

May 23, 2017

Dragonfly Therapeutics Adds Natural Killer Cell-Based Cancer Immunotherapy Expert to Its Scientific Advisory Board France - Français España - español USA - English Deutschland - Deutsch

May 15, 2017

Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting Cytomegalovirus (CMV)

May 6, 2017

Immune-Onc Therapeutics, Inc. Announces Partnership with University of Texas to Develop Novel Cancer Immunotherapy

May 4, 2017

NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership

Mar 28, 2017

Immune-Onc Therapeutics, Inc. Announces Licensing and Collaboration With Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center to Develop Novel Cancer Immunotherapy

Mar 27, 2017

APEIRON Biologics Receives Green Light for Marketing Approval of a Neuroblastoma Immunotherapy in the European Union

Mar 3, 2017

Qu Biologics Discovers Correlation Between Patient Genetics and Response to Immunotherapy in Inflammatory Bowel Disease

Feb 27, 2017

Vycellix and Moffitt Cancer Center Announce a Collaborative Research Study to Evaluate Novel Product Candidates for Improving Adoptive Cell Immunotherapies for Cancer

Feb 24, 2017

Biothera Pharmaceuticals Announces Presentation of Clinical Data Supporting Use of a Patient Selection Biomarker for its Phase 2 Cancer Immunotherapy

Feb 22, 2017

Atreca, Inc. Presents New Preclinical Findings for Novel Cancer Immunotherapy Platform at Molecular Medicine Tri-Conference 2017

Feb 21, 2017

Cell Medica: Lead Cancer Immunotherapy Candidate Receives FDA Fast Track Designation

Jan 9, 2017

Atreca, Inc. to Present Cancer Immunotherapy Platform and Data at the PepTalk 2017 Conference

Dec 12, 2016

Atreca Announces Lead Preclinical Projects in Cancer Immunotherapy and Additional Disease Indications

Dec 8, 2016

PCI Biotech and eTheRNA immunotherapies initiate research collaboration

Nov 29, 2016

Biothera Pharmaceuticals Announces Data Demonstrating Unique Immune Response Profile Generated by Phase 2 Cancer Immunotherapy Imprime PGG

Nov 11, 2016

Atreca Presents Promising Findings from Lead Antibody Program at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 8, 2016

DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform

Nov 8, 2016

Madison Vaccines Says Promising Early Data on the Combination of Its Lead Prostate Cancer Vaccine with a PD-1 Inhibitor Will Be Presented at Major Medical Meeting Nov. 11th

Nov 2, 2016

Versant Ventures Portfolio Company Turnstone Biologics Completes CAD$55.3 Million Series B

Sep 20, 2016

SAB Biotherapeutics' Immunotherapy Proposal among Top Platform Technology Solutions in WHO Report

Sep 19, 2016

PIN Pharma to Present a Poster at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Aug 24, 2016

Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications

Aug 11, 2016

Vedanta Biosciences Announces Collaboration with the NYU Langone Medical Center to Develop Microbiome-Derived Immunotherapies for Cancer

Aug 4, 2016

Juno Therapeutics Announces Multiple Myeloma Partnership with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for Developing CAR T Cell Immunotherapy Against Multiple Novel Targets

Jun 17, 2016

Cell Medica and Baylor College of Medicine Announce Exclusive Licensing Agreement and Co-Development Partnership to Create Next Generation Cellular Immunotherapy Products for the Treatment of Cancer

May 25, 2016

Intrommune Therapeutics Announces Positive Results of Proof-of-Concept study of Oral Mucosal Immunotherapy (OMIT) Platform for the Treatment of Allergies

May 24, 2016

Xenikos B.V. to introduce immunotherapy T-GuardTM to potential pharmaceutical partners at BIO International Convention 2016

May 14, 2016

Parker Institute for Cancer Immunotherapy and PsiOxus Therapeutics Announce Intention to Collaborate on Tumor-Specific Immuno-Gene Therapy

May 9, 2016

PureTech Teams with Siddhartha Mukherjee to Launch Vor BioPharma to Advance Novel Targeting Platform to Expand Applicability of CAR T-Cell Immunotherapies in Immuno-Oncology

May 2, 2016

Atreca Expands Leadership Team, Appoints Accomplished Cancer Immunotherapy Researcher and Drug Developer Norman M. Greenberg, Ph.D., as Chief Scientific Officer

May 2, 2016

Vycellix’s CEO to Present Novel Approaches to Adoptive Cancer Immunotherapy at Innate Killer Summit

Mar 29, 2016

Immunomic Therapeutics (ITI) and Lysosomal Associated Membrane Protein (LAMP) Based Nucleic Acid Immunotherapy Featured At 2016 World Vaccine Congress

Mar 29, 2016

Gadeta Closes EUR 7 Million Series A Financing to Advance Novel Cancer Immunotherapies to the Clinic

Mar 22, 2016

Quest PharmaTech's Subsidiary, OncoQuest, Signs Agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. to Fund Immunotherapy for Treatment of Cancer in China

Mar 11, 2016

Atreca Announces Presentation of Preclinical Data for Cancer Immunotherapy Program

Mar 1, 2016

Intrommune Therapeutics Announces Issuance of U.S. Patent Covering Oral Mucosal Immunotherapy for Food Allergy

Feb 22, 2016

Formula Pharmaceuticals and Rockland Immunochemicals Enter Into a Collaboration To Develop C.I.K. CAR Immunotherapy Pipeline for the Treatment of Cancer

Jan 21, 2016

Internationally Recognized Experts Appointed to SAB Biotherapeutics Scientific Advisory Board

Jan 20, 2016

Immunocore Starts Clinical Trial with IMCgp100 in Combination with MedImmune Immunotherapies Durvalumab and Tremelimumab

Jan 19, 2016

IRX Therapeutics and ImmunID Announce Collaboration to Predict Response to IRX-2 Cancer Immunotherapy Using ImmunTraCkeR

Jan 7, 2016

Eureka Therapeutics Announces Exclusive License Agreement between Memorial Sloan Kettering Cancer Center and Juno Therapeutics for Use of a Novel, Fully-Human MUC16 Binder in CAR T Cell Immunotherapy

Nov 18, 2015

Quest PharmaTech's Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement with Hepalink USA to Fund Immunotherapy for Treatment of Cancer

Nov 9, 2015

Replicor Announces Grant of US Patents on HBV / HDV Treatment Methods Combining HBsAg Reduction and Immunotherapy

Nov 5, 2015

Intensity Therapeutics Preclinical Results Show Anti-Cancer Synergy of INT230-6 with Anti-PD-1 Compounds

Nov 4, 2015

Atreca, Inc., Completes Oversubscribed $56 Million Series A Funding to Advance Pipeline of Novel Cancer Immunotherapies

Nov 3, 2015

Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting

Nov 3, 2015

CureVac raises $110 Million in a private placement

Aug 10, 2015

Evotec, Apeiron Biologics and Sanofi Jointly Develop Novel Small Molecule-Based Cancer Immunotherapies

Aug 3, 2015

Formula Pharmaceuticals and the Max Delbrück Center for Molecular Medicine Enter Into an Exclusive Licensing Agreement and Strategic Collaboration to Develop C.I.K. CAR™ Immunotherapies

Jul 7, 2015

CureVac Announces Phase I/IIa Clinical Study Data of its mRNA Cancer Immunotherapy in Prostate Cancer Published in the Journal for ImmunoTherapy of Cancer

May 11, 2015

Formula Pharmaceuticals Acquires Next-Generation, Allogeneic, Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform; Completes Private Fundraising

May 4, 2015

Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies

Apr 20, 2015

Immunocore Announces Positive Clinical Trial Data for Novel First-in-Class Immunotherapy at AACR Annual Meeting 2015

Mar 24, 2015

Affimed Completes TandAb Development Candidate Activities Meeting Amphivena's and Janssen's Criteria and Achieves Milestone Ahead of Schedule

Feb 17, 2015

Agilvax Announces Strategic Collaboration with Humabs BioMed SA to Develop Targeted Vaccines and Immunotherapies

Feb 9, 2015

Lycera Announces Research Showing Promising Anti-Cancer Activity of Novel, Oral Immunotherapy Candidates

Dec 22, 2014

ImmusanT Raises $12 Million in Series B Financing

Dec 11, 2014

Batu Biologics Submits Investigational New Drug Application for Lung Cancer Anti-Angiogenic Immunotherapy with FDA

Nov 11, 2014

Batu Biologics Recruits Inventor of Licensed UCSD Cancer Immunotherapy to Scientific Advisory Board

Nov 7, 2014

Lycera Announces Research Showing Novel, Oral Immunotherapy Possesses Potent Single Agent Anti-Cancer Activity

Nov 5, 2014

Invetech And Argos Therapeutics Announce Agreement To Support Global Production Of Fully Personalized Immunotherapies

Oct 31, 2014

Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting

Oct 9, 2014

Intensity Therapeutics, Inc.’s Research Selected for Presentation at the Annual National Cancer Institute Cancer Immunology and Immunotherapy Conference

Sep 18, 2014

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

Jul 27, 2014

Batu Biologics Strategy for FDA Approval of Lung Cancer Immunotherapy Featured in San Diego Business Journal

Jul 17, 2014

Batu Biologics’ Lung Cancer Immunotherapy Featured in CEOCFO Magazine

May 30, 2014

Promedior to Present Positive Preliminary Phase 2 Data for PRM-151 in Myelofibrosis at ASCO Annual Meeting

May 9, 2014

Batu Biologics Files Patent Covering New Use of Approved Drug for Decreasing Cancer Immunotherapy Toxicity

Mar 25, 2014

AvidBiotics Granted U.S. Patent for Novel Immunotherapeutic Platform

Mar 19, 2014

Argos Therapeutics to Present at Regenerative Medicine and Cancer Immunotherapy Meetings

Jan 7, 2014

Cell Medica Announces Orphan Drug Designation in the European Union for Cytovir ADV

Nov 11, 2013

Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma

Nov 8, 2013

Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD

Nov 4, 2013

CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer

Aug 27, 2013

Argos Therapeutics Secures $42.5 Million Financing, Funds Pivotal Phase 3 ADAPT Trial for Personalized Immunotherapy

Apr 19, 2013

ImmusanT's Epitope-Specific Immunotherapy for Celiac Disease Informs the Potential of Vaccines Against Other Autoimmune Diseases

Jan 2, 2013

Evotec and Apeiron Biologics Announce Collaboration on Cancer Immunotherapy

Sep 5, 2012

ImmuNext Enters into a Strategic Partnership with Janssen to Develop Novel Immunotherapies for the Treatment of Cancer

Apr 24, 2012

Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012

Jun 28, 2011

Argos Therapeutics to Participate in Panel Discussion on Innovative Approaches to HIV Vaccine Development and Immunotherapies at 2011 BIO International Convention

Jun 1, 2011

Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes

May 4, 2011

Argos Therapeutics' Immunotherapy Platform Based on Recombinant Human Soluble CD83 Demonstrates Significant Promise For Solid Organ Transplantation

Mar 15, 2011

Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy

Dec 9, 2010

Argos Therapeutics' Arcelis™ HIV Immunotherapy Shows Feasibility to Generate Fully Functional Dendritic Cells From Viremic Patients

Nov 2, 2010

Argos Therapeutics to Present About the Implementation, Cost Effectiveness and Benefits of Automation for its Arcelis™ Immunotherapy at The Cell Therapy Industry Summit-2010

Oct 28, 2010

Argos Therapeutics to Present a Corporate Overview, Prospects of its Arcelis™ Immunotherapy and Clinical Developments at 2010 Mid-Atlantic Bio

Oct 18, 2010

Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference